Mobile

A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in ...

Update Il y a 5 ans
Reference: EUCTR2006-001511-30

A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in patients with prostate cancer

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Part A: To determine the proportion of patients remaining medically castrated (serum testosterone level < 50 ng/dL) at Day 240 following two SC administrations of a 4-month sustained-release (SR) formulation of Triptorelin.

Inclusion criteria

  • Locally advanced or metastatic prostate cancer

Links